

Product Information

Tamoxifen

Powder, Suitable for cell culture

T2859

Product Description

Tamoxifen is a selective estrogen response modifier (SERM), protein kinase C inhibitor and anti-angiogenetic factor. Tamoxifen is a prodrug that is metabolized to active metabolites 4-hydroxytamoxifen (4-OHT) and endoxifen by cytochrome P450 isoforms CYP2D6 and CYP3A4. Tamoxifen blocks estradiol-stimulated VEGF production in breast tumor cells.

Precautions and Disclaimer

For R&D use only. Not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

Storage/Stability

Store this product at 2-8 °C.

Preparation Instructions

Tamoxifen is soluble in chloroform at 50 mg/mL and yields a clear, colorless to faint yellow solution. Stock solutions of Tamoxifen can also be prepared in DMSO at 10 mM. It is also soluble in methanol, ethanol, 2-propanol and propylene glycol. However, it is practically insoluble in water (solubility is <0.01%, 20 °C). DMSO solutions are stable when stored at -20 °C in the dark. Solutions are sensitive to UV light.

Activity

Tamoxifen has been used to facilitate the recombination of ect2flox allele in mouse organs. It has also been used to study its effect on lipopolysaccharide (LPS)-induced microglial activation.

Tamoxifen is a protein kinase C inhibitor. Induces apoptosis in human malignant glioma cell lines. Tamoxifen and its metabolite 4-hydroxytamoxifen are selective estrogen response modifiers (SERMs) that act as estrogen antagonists in mammary gland. Blocks estradiol-stimulated VEGF production in breast tumor cells.

References

1. Chemical Abstracts Registry data, American Chemical Society.
2. Material Safety Data Sheet.
3. Quality Control data.
4. The Merck Index, 12th, #9216, (1996).
5. Physicians' Desk Reference, 47th ed., 1126, (1993).
6. Beggs, W.H.J. Antimicrob. Chemother. 37, 841, (1996).
7. Bottega, R. and Epand, R.M. Biochem. 31, 9025, (1992).
8. Supplier Data.
9. Furr, B.J.A. and Jordan, V.C. Pharmac. Ther. 25, 127, (1984).
10. Al-Hassan, M.I. Synth. Commun. 17, 1247, (1987).
11. Sastry, C.S.P. et al., Talanta, 42, 1479, (1995).
12. Sastry, C.S.P. and Lingeswara Rao, J.S.V.M., Indian J. Pharm. Sci. 57, 133, (1995).
13. Berthou, F. and Dreano, Y., J. Chromatogr. 616, 117, (1993).
14. Weir, P.J. et al., J. Pharm. Biomed. Anal. 7, 393, (1989).
15. Jalonen, H.G.J. Pharm. Sci. 77, 810, (1988).

16. Adam, H.K. Non-Steroidal Antioestrogens: Mol. Pharmacol. Antitumor Act., eds. Sutherland, R.L. and Jordan, V.C., Academic, Sydney, Australia, 1981, 59.
17. Murphy, C. et al., J. Steroid Biochem. 26, 547, (1987).
18. Precigoux, G. et al., Acta Cryst. B35:3070, (1979).
19. Lau, C.K. et al., Proc. Natl. Acad. Sci. USA, 88, 829, (1991).
20. Issandou, M. et al., Cancer Res. 50, 5845, (1990).
21. O'Brian, C.A. et al., Cancer Res. 45, 2462, (1985).
22. Gold, E. et al., Horm. Metab. Res. 26, 100, (1994).
23. Han, Y. and Liehr, J.G. Cancer Res. 52, 1360, (1992).
24. Kuramochi, H., J. Med. Chem. 39, 2877, (1996).
25. Pienta, K.J. et al., The Prostate 26, 270, (1995).
26. Danova, M. et al., Annals NY Acad. Sci. 698, 174, (1993).
27. Edwards, K.J. et al., J. Med. Chem. 35, 2753, (1992).
28. Powis, G. Trends Pharmacol. Sci. 12, 188, (1991).
29. Wiseman, H. Methods in Enzymol. 234, 590, (1994).
30. Martindale, The Extra Pharmacopoeia, 30th ed. 500, (1993).
31. Goodman and Gilman's The Pharmacological Basis of Therapeutics, Seventh ed. 1297, 1424, (1985).
32. Jordan, V.C. et al., Molecular and Cellular Endocrinology, 7, 177, (1977).
33. Nicholson, R.I. and Griffiths, K. Advances in Sex Hormone Res. 4, 119, 1980.
34. Jordan, V.C. Annu. Rev. Pharmacol. Toxicol. 35, 195, (1995).
35. Jordan, V.C. Breast Cancer Research and Treatment, 2, 123, (1982) (review).
36. Buckley, M.M.T. and Goa, K.L. Drugs 27, 451, (1989) (review).
37. Duax, W.L. et al. Environmental Health Perspectives, 61, 111, (1985).

Notice

We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.

The information in this document is subject to change without notice and should not be construed as a commitment by the manufacturing or selling entity, or an affiliate. We assume no responsibility for any errors that may appear in this document.

Technical Assistance

Visit the tech service page at [SigmaAldrich.com/techservice](https://www.SigmaAldrich.com/techservice).

Terms and Conditions of Sale

Warranty, use restrictions, and other conditions of sale may be found at [SigmaAldrich.com/terms](https://www.SigmaAldrich.com/terms).

Contact Information

For the location of the office nearest you, go to [SigmaAldrich.com/offices](https://www.SigmaAldrich.com/offices).

The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.

MilliporeSigma, and Sigma-Aldrich are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.

© 2022 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

T2859pis Rev 0822

**Millipore
Sigma**